Nikon CeLL innovation, a subsidiary of Nikon Corporation, announced the completion of a commercial scale technology transfer from RoosterBio for the manufacturing of human mesenchymal stem cells and extracellular vesicles.
The transferred technology covers the expansion harvest formulation and cryopreservation of stem cells using both 2D flasks and stirred tank 3D bioreactors. It also includes processes for producing harvesting and purifying extracellular vesicles derived from mesenchymal stem cells.
With this transfer Nikon CeLL innovation will provide end to end solutions in Japan covering process development analytical characterization and manufacturing under GCTP and GMP standards.
The collaboration follows a strategic licensing agreement announced in 2025 between Nikon CeLL innovation and RoosterBio. The platform supports manufacturing systems ranging from small scale cell culture to bioreactors up to 50 liters.
The expanded capability aims to support pharmaceutical companies and research organizations developing cell and gene therapies by improving manufacturing capacity and project development timelines.
Leave a comment